Lantern Pharma (NASDAQ:LTRN) Earns “Neutral” Rating from HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Lantern Pharma (NASDAQ:LTRN) in a research report report published on Thursday, Benzinga reports.

Lantern Pharma Stock Performance

Shares of Lantern Pharma stock opened at $5.50 on Thursday. Lantern Pharma has a one year low of $2.38 and a one year high of $11.99. The stock’s 50-day moving average is $6.76 and its 200 day moving average is $4.83.

Lantern Pharma (NASDAQ:LTRN) last announced its earnings results on Monday, March 18th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.01. Analysts expect that Lantern Pharma will post -2.02 EPS for the current fiscal year.

Insiders Place Their Bets

In other Lantern Pharma news, major shareholder Aaron G.L. Fletcher sold 74,297 shares of the stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $4.85, for a total value of $360,340.45. Following the transaction, the insider now owns 62,088 shares in the company, valued at $301,126.80. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 6.92% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Lantern Pharma stock. Meridian Wealth Management LLC purchased a new position in Lantern Pharma Inc. (NASDAQ:LTRN) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 16,660 shares of the company’s stock, valued at approximately $57,000. Meridian Wealth Management LLC owned approximately 0.15% of Lantern Pharma as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 28.62% of the company’s stock.

Lantern Pharma Company Profile

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.